

ACADEMIC PUBLICATIONS:

1. Poh XY[†], **Torres-Ruesta A[†]**, Yoong T, Wong N, Tan CW, *et al.* Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. **Vaccine**. Epub 2024 Sep 5.
2. Poh XY, Lee IR, Tan CW, Chavatte JM, Fong SW, Goh YS, Rouers A, Wong N, **Torres-Ruesta A**, *et al.* First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial. **EBioMedicine**. Epub 2024 Aug 12.
3. Ho VWT, Boon LH, Cui J, Juequn Z, Shunmuganathan B, Gupta R, Tan NYJ, Qian X, Purushotorman K, **SCOPE Cohort Study Group***, *et al.* Relative deficiency in interferon- γ -secreting CD4⁺ T cells is strongly associated with poorer COVID-19 vaccination responses in older adults. **Aging Cell**. 2024 Apr;23(4):e14099.
4. Lum FM, Chan YH, Teo TH, Becht E, Amrun SN, Teng KW, Hartimath SV, Yeo NK, Yee WX, Ang N, **Torres-Ruesta A**, *et al.* Crosstalk between CD64⁺MHCII⁺ macrophages and CD4⁺ T cells drives joint pathology during chikungunya. **EMBO Mol Med**. 2024 Feb 8.
5. Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer- Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L, NCID Study Group, **COVID-19 Cohort Study Group***, *et al.* Variant-specific IgA protects against Omicron infection. **J Infect Dis**. 2023 Nov 23;jjad525.
6. Goh YS, Fong SW, Tay MZ, Rouers A, Chang ZW, Chavatte JM, Hor PX, Loh CY, Huang Y, Tan YJ, Wang B, Ngoh EZX, Mohd Salleh SN, Lee RTC, Lim G, NCID Study Group , **COVID-19 Study Group***, *et al.* Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave. **Sci Rep**. 2023 Nov 7;13(1):19331.
7. Fong SW, Goh YS, **Torres-Ruesta A**, *et al.* Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection. **J Med Virol**. 2023 May;95(5):e28774.
8. Tay MZ, Goh YS, Fong SW, Chang ZW, Rouers A, Wong N, **Torres-Ruesta A**, *et al.* Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant. **Lancet Reg Health West Pac**. 2023 Apr;33:100732.
9. Goh YS, Rouers A, Fong SW, Zhuo NZ, Hor PX, Loh CY, Huang Y, Neo VK, Kam IKJ, Wang B, Ngoh EZX, Salleh SNM, Lee RTC, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES; NCID Study Group; **COVID-19 Study Group***; *et al.* Waning of specific antibodies against Delta and Omicron variants five months

after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. *Front Immunol*. 2022 Nov 14;13:1031852.

10. Rouers A, Wong N, Goh YS, **Torres-Ruesta A**, *et al*. Efficient recall of SARS-CoV-2 variant- reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters. *J Med Virol*. 2023 Jan;95(1):e28258.
11. Lum FM, **Torres-Ruesta A**, Tay MZ, Lin RTP, Lye DC, Rénia L, Ng LFP. Monkeypox: disease epidemiology, host immunity and clinical interventions. *Nat Rev Immunol*. 2022 Sep 5:1–17.
12. Renia L, Goh YS, Rouers A, Le Bert N, Chia WN, Chavatte JM, Fong SW, Chang ZW, Zhuo NZ, Tay MZ, Chan YH, Tan CW, Yeo NK, Amrun SN, Huang Y, Wong JXE, Hor PX, Loh CY, Wang B, Ngoh EZX, Salleh SNM, Carissimo G, Dowla S, Lim AJ, Zhang J, Lim JME, Wang CI, Ding Y, Pada S, Sun LJ, Somani J, Lee ES, Ong DLS; ***SCOPE Cohort Study Group**, *et al*. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. *Nat Commun*. 2022 Aug 8;13(1):4615.
13. Goh YS, Fong SW, Rouers A, Chang ZW, Tay MZ, Chavatte JM, Zhuo NZ, Hor PX, Loh CY, Huang Y, Wong JXE, Tan YJ, Lim DRX, Wang B, Ngoh EZX, Salleh SNM, Lee RTC, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES; NCID Study Group; ***COVID-19 Study Group**, *et al*. Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. *Clin Transl Immunology*. 2022 Aug 23;11(8):e1403.
14. **Torres-Ruesta A**, Teo TH, Chan YH, Amrun SN, Yeo NK, *et al*. Malaria abrogates O'nyong-nyong virus pathologies by restricting virus infection in nonimmune cells. *Life Sci Alliance*. 2022 Jan 17;5(4):e202101272.
15. Tay MZ, Rouers A, Fong SW, Goh YS, Chan YH, Chang ZW, Xu W, Tan CW, Chia WN, **Torres-Ruesta A**, *et al*. Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. *EMBO Mol Med*. 2022 Mar 7;14(3):e15227.
16. Lim J, Puan KJ, Wang LW, Teng KWW, Loh CY, Tan KP, Carissimo G, Chan YH, Poh CM, Lee CY, Fong SW, Yeo NK, Chee RS, Amrun SN, Chang ZW, Tay MZ, **Torres-Ruesta A**, *et al*. Data- Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. *Front Immunol*. 2021 Nov 19;12:710217.
17. Fong SW, Yeo NK, Chan YH, Goh YS, Amrun SN, Ang N, Rajapakse MP, Lum J, Foo S, Lee CY, Carissimo G, Chee RS, **Torres-Ruesta A**, *et al*. Robust Virus-Specific Adaptive Immunity in COVID- 19 Patients with SARS-CoV-2 Δ 382 Variant Infection. *J Clin Immunol*. 2022 Feb;42(2):214-229.
18. Wang B, Goh YS, Fong SW, Young BE, Ngoh EZX, Chavatte JM, Salleh SNM, Yeo NK, Amrun SN, Hor PX, Loh CY, Lee CY, Chan YH, Chang ZW, Tay MZ, Rouers A, **Torres-Ruesta A**, *et al*. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. *Lancet Reg Health*

West Pac. 2021 Oct;15:100276.

19. Chan YH, Fong SW, Poh CM, Carissimo G, Yeo NK, Amrun SN, Goh YS, Lim J, Xu W, Chee RS, **Torres-Ruesta A**, *et al.* Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. **EMBO Mol Med.** 2021 Jun 7;13(6):e14045.
20. **Torres-Ruesta A**, Chee RS, Ng LFP. Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape. **Microorganisms.** 2021 Apr 22;9(5):899.
21. Lee CY, Amrun SN, Chee RS, Goh YS, Mak TM, Octavia S, Yeo NK, Chang ZW, Tay MZ, **Torres-Ruesta A**, *et al.* Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant. **Clin Transl Immunology.** 2021 Feb 22;10(2):e1241.
22. Amrun SN, Lee CY, Lee B, Fong SW, Young BE, Chee RS, Yeo NK, **Torres-Ruesta A**, *et al.* Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. **EBioMedicine.** 2020 Aug;58:102911.
23. Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY, Chee RS, Fong SW, Yeo NK, Lee WH, **Torres-Ruesta A**, *et al.* Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. **Nat Commun.** 2020 Jun 1;11(1):2806.
24. Chan YH, Teo TH, **Torres-Ruesta A**, Hartimath SV, Chee RS, Khanapur S, *et al.* Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus Infection. **Front Immunol.** 2020 May 12;11:894.
25. Lee CY, Carissimo G, Chen Z, Lum FM, Abu Bakar F, Rajarethinam R, Teo TH, **Torres-Ruesta A**, *et al.* Type I interferon shapes the quantity and quality of the anti-Zika virus antibody response. **Clin Transl Immunology.** 2020 Apr 26;9(4):e1126.
26. **Torres-Ruesta A**, Teo TH, Chan YH, Rénia L, Ng LFP. Pathogenic Th1 responses in CHIKV-induced inflammation and their modulation upon Plasmodium parasites co-infection. **Immunol Rev.** 2020 Mar;294(1):80-91. doi: 10.1111/imr.12825.
27. Carissimo G, Teo TH, Chan YH, Lee CY, Lee B, **Torres-Ruesta A**, *et al.* Viperin controls chikungunya virus-specific pathogenic T cell IFN γ Th1 stimulation in mice. **Life Sci Alliance.** 2019 Jan 21;2(1):e201900298.

†Under co-first authorship.

*Under group authorship.